Literature DB >> 9739110

Reserpine attenuates D-amphetamine and MDMA-induced transmitter release in vivo: a consideration of dose, core temperature and dopamine synthesis.

K E Sabol1, L S Seiden.   

Abstract

Amphetamine releases dopamine through a transporter-mediated mechanism. The purpose of this report was to further our understanding of the intracellular pool from which amphetamine releases dopamine: the cytoplasmic pool, the vesicular pool, or both. Rats were treated with D-amphetamine (AMPH) (1.0 or 10.0 mg/kg) or an amphetamine analog, methylenedioxymethamphetamine (MDMA) (2.0, 5.0, or 10.0 mg/kg). Pre-treatment with 10.0 mg/kg reserpine (18 h prior to AMPH or MDMA) attenuated dopamine release for high and low AMPH doses; however the low-dose effect showed borderline significance. Pre-treatment with 10.0 mg/kg reserpine attenuated dopamine and serotonin release induced by MDMA. The dopamine effect was seen at all three MDMA doses; the effect on serotonin was only measured at the 10.0 mg/kg dose. Reserpine pre-treatment caused reductions in core body temperature; heating the rats to normal body temperature for 3 h prior to AMPH or MDMA, and during the 4 h post-treatment period partially reversed the reserpine-induced attenuation of dopamine release. However, the intermediate level of dopamine release for the reserpinized-heated animals was not significantly different from either the reserpine group (not heated) or the AMPH or MDMA alone groups. In a separate group of rats, the effects of reserpine and reserpine+heat on dopamine synthesis were measured. DOPA accumulation after treatment with the aromatic acid decarboxylase inhibitor NSD-1015 (100 mg/kg, 30 min before sacrifice), was greater in rats treated with reserpine compared to controls; heating the reserpinized rats did not significantly alter the amount of DOPA accumulation; however there was a trend towards further increase. These results suggest that D-amphetamine releases dopamine that is stored in both vesicles and the cytoplasm. Cooling may contribute to the attenuation of AMPH or MDMA-induced dopamine release observed after reserpine; however, AMPH or MDMA dependence upon vesicular stores most likely explains the diminished release after reserpine. The attenuation of AMPH or MDMA-induced transmitter release by reserpine is thought to be counteracted by a reserpine-induced replenishment of stores. Therefore, all doses of D-amphetamine may use vesicular stores; the degree to which new synthesis counteracts the vesicular depletion may be the variable which differentiates low from high doses of D-amphetamine. Copyright 1998 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9739110     DOI: 10.1016/s0006-8993(98)00720-3

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  17 in total

1.  Investigation of the mechanisms mediating MDMA "Ecstasy"-induced increases in cerebro-cortical perfusion determined by btASL MRI.

Authors:  J Rouine; M E Kelly; C Jennings-Murphy; P Duffy; I Gorman; S Gormley; C M Kerskens; Andrew Harkin
Journal:  Psychopharmacology (Berl)       Date:  2014-11-01       Impact factor: 4.530

2.  Sex and strain differences in dynamic and static properties of the mesolimbic dopamine system.

Authors:  Maria Teresa Rivera-Garcia; Aqilah M McCane; Tara G Chowdhury; Kathryn G Wallin-Miller; Bita Moghaddam
Journal:  Neuropsychopharmacology       Date:  2020-07-14       Impact factor: 7.853

3.  Cocaine self-administration produces pharmacodynamic tolerance: differential effects on the potency of dopamine transporter blockers, releasers, and methylphenidate.

Authors:  Mark J Ferris; Erin S Calipari; Yolanda Mateo; James R Melchior; David C S Roberts; Sara R Jones
Journal:  Neuropsychopharmacology       Date:  2012-03-07       Impact factor: 7.853

4.  A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brain.

Authors:  M I Colado; J Camarero; A O Mechan; V Sanchez; B Esteban; J M Elliott; A R Green
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

5.  Methylenedioxymethamphetamine inhibits mitochondrial complex I activity in mice: a possible mechanism underlying neurotoxicity.

Authors:  Elena Puerta; Isabel Hervias; Beatriz Goñi-Allo; Steven F Zhang; Joaquín Jordán; Anatoly A Starkov; Norberto Aguirre
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

6.  The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats.

Authors:  Annis O Mechan; Blanca Esteban; Esther O'Shea; J Martin Elliott; M Isabel Colado; A Richard Green
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

7.  Behavioral effects of bidirectional modulators of brain monoamines reserpine and d-amphetamine in zebrafish.

Authors:  Evan Kyzar; Adam Michael Stewart; Samuel Landsman; Christopher Collins; Michael Gebhardt; Kyle Robinson; Allan V Kalueff
Journal:  Brain Res       Date:  2013-07-01       Impact factor: 3.252

Review 8.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

Review 9.  Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons.

Authors:  Gary A Gudelsky; Bryan K Yamamoto
Journal:  Pharmacol Biochem Behav       Date:  2007-10-16       Impact factor: 3.533

Review 10.  Developmental effects of 3,4-methylenedioxymethamphetamine: a review.

Authors:  Matthew R Skelton; Michael T Williams; Charles V Vorhees
Journal:  Behav Pharmacol       Date:  2008-03       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.